We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
Staark makes cycling clothing that aims to cater to all body shapes. The company argues that current premium cycling and spin brands are cut to a single shape, optimised for the top 20% of cyclists. Staark intends to change this and bring its products to 80% of cyclists with high disposable income who are not ‘elite’ shaped. It delivers a fit based on specific body shapes using Dimensioning Technology (DT). Staark asserts that its innovative designs target cycling and indoor/spin for both men and women, with future diffusion into the wider Athleisure market, which is set to be worth $517 billion by 2025. The company has indicated that Spring 2021 is when it expects to launch its products. Staark will use the investment to enable the company to run its first productions, fueling the initial product launch.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £161,035
Brew Monster is a Cwmbran-based microbrewery and also the winner of Beverage Industry Award in the Cardiff Regional Awards 2018. It serves primarily the South Wales region, including Cardiff, Newport and Swansea, and is increasingly gaining nation-wide popularity. In just 16 months since its establishment in 2017, Brew Monster has garnered a quarterly turnover of approximately £70,000 (Oct-Dec 2018). In this short period of time, the brewery has also doubled their production capacity, established a profitable micropub and set up a brewery tap.
days to go: Expired investment: £99,250
Ubiqutek is pioneering the use of electricity in the weed control market. http://ubiqutek.com/ 
days to go: Expired investment: £133,065
We created FlyFit with the aim to change the way people travel. Air travel can be stressful, lonely, and unhealthy. On top of this, with average layovers of 2+ hours, flight delays, and hours waiting in security, there is too much unproductive time in airports with limited healthy options to choose from.
days to go: Expired investment: £500,060
The Cannabis Oil Company is an ethically led UK-based company. It manufactures an extensive range of CBD products with its 30,000 square foot distribution of research facility. The Cannabis Oil Company determines the benefits of CBD and how its usage can help people. It strives to offer high-quality products to its consumers with unparalleled manufacturing standards and end-to-end traceability. It has already secured 100 Acres of arable land, and within the next two-years, TCOC will plant its first crop. The company is planning to invest in research and development with the support of medical professionals, and it will carry its own in-depth research into the benefits of CBD with problems such as anxiety, insomnia, IBS and more.
days to go: Expired investment: £361,490
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.   
days to go: Expired investment: £30,564
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph